Amicus Therapeutics Inc
WKN: A0MSMZ / ISIN: US03152W1099Amicus Therapeutics Inc.- AOMSMZ -
Quelle:
http://files.shareholder.com/downloads/AMTX/...s_2013_1_7_General.pdf
http://amicusrx.com/
http://www.bloomberg.com/quote/FOLD:US
ausserdem:
Zitat:"Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase
2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe
Disease
Strong Proof-of-Concept Data for Chaperone's Ability to Stabilize and Enhance
Activity and Uptake of Currently Marketed ERT Products for Pompe Disease
Results to be Presented at LDN WORLD Symposium in February 2013
Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13 " ENDE ZITAT
Quelle:http://www.bloomberg.com/article/2013-01-04/a89MqiFNfOi0.html
Ausblick für 2019
- Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance
- 2019 Galafold Revenue Expected to Nearly Double – with Guidance of $160M-$180M
http://ir.amicusrx.com/news-releases/...l-year-2019-strategic-outlook
Amicus meldet Zahlen für Q1/19
- Umsatz 34 Mio. $
- Verlust 120 Mio. $
- Cash 438 Mio. $
http://ir.amicusrx.com/news-releases/...-first-quarter-2019-financial
Wie stark werden die Ergebnisse von Sanofi´s Phase3 "Pompe Disease neoGAA" ausfallen?
https://www.fool.com/investing/2019/09/11/...cs-tanked-in-august.aspx
- 2020-er Galafold Umsatz-Prognose 250-260 Mio. $
https://seekingalpha.com/news/...therapeutics-fy-2019-top-line-up-100
Zahlen für Q3/20
- Galafold 3Q20 Revenue of $67.4 Million
- On-Track to Achieve Revenue Guidance of $250M-$260M
- AT-GAA Phase 3 PROPELStudy Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20
https://ir.amicusrx.com/news-releases/...third-quarter-2020-financial
AT-GAA Phase 3 PROPEL Ergebnisse sind da
Und diese fallen schwächer aus als erwartet. Manche Marktbeobachter sind der Meinung das die Studienergebnisse nicht ausreichend für eine Zulassung sein könnten, FOLD hält dennoch an seinen Plänen fest zu versuchen die Zulassung zu erhalten.
https://ir.amicusrx.com/news-releases/...ful-significant-improvements
Phase3 PROPEL Studienergebnisse - Slideshow
https://seekingalpha.com/article/...-propel-topline-results-slideshow
- Galafold® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M
- 1Q21 Total Galafold Revenue of $66.4M
- Positive Pre-BLA Meeting Held with U.S. FDA for AT-GAA in Pompe Disease; Rolling BLA Submission On-Track for Completion in 2Q21
https://ir.amicusrx.com/news-releases/...first-quarter-2021-financial
vorläufige Zahlen
- FY21 Galafold Umsätze 306 Mio. $
- FY22 Galafold Umsatzprognose 350-365 Mio. $
https://ir.amicusrx.com/news-releases/...preliminary-2021-revenue-and
Die durchschnittlichen Umsatzerwartungen der Analysten für 2022 liegen bei ~396 Mio. $
Zahlen für Q1/22
- Galafold Umsätze 78,7 Mio. $
- FY22 Galafold Umsatzprognose 350-365 Mio. $
- FY22 Galafold Umsatzprognose 350-365 Mio. $
- Verlust 85 Mio. $
- Cash 411 Mio. $
- MK 1,8 Mrd. $
https://ir.amicusrx.com/news-releases/...first-quarter-2022-financial